Skip to main content
Top

22-06-2023 | Non-Hodgkin Lymphoma | Congress News | News

EHA 2023

Relapsed and refractory PTCL treatments mapped

MedNet.nl: The optimal treatment of relapsed and refractory (R/R) peripheral T-cell lymphoma (PTCL) is as yet unknown. Dutch population-based research provides insight into the most commonly used treatment strategies for this patient group.

Related topics

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine